Basking Ridge, NJ – According to filings with the U.S. Securities and Exchange Commission, Caladrius Biosciences is raising $25,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, David Mazzo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. At Caladrius Biosciences, our mission is to bring new, innovative and treatment paradigm-changing medical therapies to market based on our unique expertise and experience, and in so doing, to improve patients’ lives and create value for our shareholders.

To learn more about Caladrius Biosciences, visit http://www.caladrius.com/

Contact:
David Mazzo, President and Chief Executive Officer
908-842-0100
dmazzo@caladrius.com
https://www.linkedin.com/in/david-mazzo-76b13912/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved